Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484885 | 0.87 | ALDH1A1 (0.44) | MAPTCYP2C19GAACYP2C9MEN1 | |
| SCHEMBL983425 | 0.87 | CYP1A2 (0.57) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL18050572 | 0.85 | TSHR (0.44) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL4625676 | 0.84 | TSHR (0.56) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL1546638 | 0.83 | CYP2C19 (0.49) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL10915358 | 0.82 | ALDH1A1 (0.45) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL18050726 | 0.81 | HSP90AA1 (0.49) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL14279020 | 0.81 | TSHR (0.52) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL164673 | 0.81 | TSHR (0.52) | TSHRMAPTCYP2C19GAACYP2C9 | |
| SCHEMBL3999898 | 0.80 | KDM4E (0.55) | TSHRMAPTGAANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964724-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964724-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090143364-A1 | CHIRAL CIS-IMIDAZOLINES | FOTOUHI NADER | 2009-06-04 | — | — | US | disclosed |
| US-20090143364-A1 | CHIRAL CIS-IMIDAZOLINES | FOTOUHI NADER | 2009-06-04 | — | — | US | disclosed |
| EP-1753727-B1 | NOVEL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| EP-1753727-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| US-20050288287-A1 | Chiral cis-imidazolines | FOTOUHI NADER | 2005-12-29 | — | — | US | disclosed |
| WO-2005110996-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143364-A1 | CHIRAL CIS-IMIDAZOLINES | TP53, MDM2, TP53BP1 | TSHR 1791/4885MAPT 2665/4885CYP2C19 2368/4885 |
| US-20050288287-A1 | Chiral cis-imidazolines | TP53, MDM2, TP53BP1 | TSHR 1791/4885MAPT 2665/4885CYP2C19 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.